BioNTech SE
https://biontech.de/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioNTech SE
Pfizer’s Dolsten Plans Exit, Ushering In R&D Transition
Chief scientific officer and president of Pfizer Research & Development Mikael Dolsten will depart the company after a successor is appointed, likely early next year.
Top 10 Drugs Q1 2024: Keytruda Reigns, Trikafta Debuts
Keytruda enjoyed its fifth consecutive quarter as the world’s top-selling drug in the first three months of 2024. As Comirnaty and Spikevax fell out of the list, Vertex’s cystic fibrosis pill Trikafta/Kaftrio became one of the top 10 best-selling drugs for the first time.
GSK Looks To Catch Up In mRNA Vaccines With New CureVac Deal
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
Amid Growing Pandemic Fears, Moderna Gets BARDA Funding For Flu Program
The biotech got a $176m award for its pandemic influenza vaccine program through BARDA’s Rapid Response Partnership Vehicle.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
-
- BioNTech US Inc.
- Biopharmaceutical New Technologies AG
- Neon Therapeutics, Inc.
- BioNTech AG
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice